Forward P/S Multiple: Catalent Pharma Solutions (CTLT)

Corporate company logo of Catalent, Inc (CTLT)

Catalent, Inc. (CTLT) is facing debt pressure and volatility in vaccine demand. Business efficiency is based on the delegation of IT processes and raw material procurement. However, the foundation of success is an automated task distribution system that eliminates vendor dependency. The forward P/S ratio clearly demonstrates the valuation-to-revenue dynamics, where 2.60 represents the current metric.

CTLT (catalent.com) Price to Expected Revenue Ratio history from 07/04/2022 to 01/04/2025

Catalent, Inc (CTLT) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price Catalent|CTLT - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Catalent, Inc|CTLT - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Catalent|CTLT - Total Net Assets|Market Capitalization to Book Value Ratio catalent.com|CTLT - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Catalent, Inc.|CTLT - Long-Term Debt to Equity|Short-Term Debt to Capital Catalent, Inc.|CTLT - Company Cumulative Debt|Debt to Book Capitalization Ratio Catalent, Inc|CTLT - Company Long-Term Indebtedness|Company Current Liabilities Catalent|Quick Liquidity Indicator catalent.com
- net income and valuation multiples indicators:
CTLT - Final Profit|Projected Future Earnings Catalent, Inc.|CTLT - Business Payback Period|Future Price to Earnings Catalent Pharma Solutions|CTLT - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Catalent, Inc|CTLT - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Catalent|CTLT - Net earnings per share for the last four quarters|Quarterly EPS earnings growth catalent.com|CTLT - Net earnings per share growth this year|Expected earnings per share growth for next year Catalent, Inc.
- issuer revenue and sales details:
CTLT - Company Total Sales|Company Projected Revenue Catalent|CTLT - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Catalent, Inc
Initial company analysis:CTLT (Catalent)
Original product of Catalent, Inc

Driven by long-term biopharmaceutical contracts, Catalent, Inc. (CTLT) demonstrates high resilience to macroeconomic fluctuations. By analyzing the projected P/S multiple, an investor correlates current market capitalization with expected revenue, enabling an assessment of future cash flows and preventing overpayment for the asset during periods of shifting market expectations.

Competitor analysis for Catalent, Inc.

Forward P/S Multiple IQV (IQVIA)|LH - Forward Price-to-Revenue Multiple|Medpace Inc. - Forward P/S Multiple|ICLR - Forward P/S Multiple|CRL (Charles River Laboratories) - Forward Price-to-Revenue Multiple|EVO: Price to Expected Revenue Ratio|FTRE (Fortrea) - Forward P/S Multiple|Forward P/S Multiple Lifecore|Price-to-Projected Revenue Ratio OmniAb Corp (OABI)|Price-to-Projected Revenue Ratio NOTV (Inotiv Corporation)|Forward P/S Multiple CDMO (Avid Bioservices, Inc.)|nighthawkbio.com (SCPX) - Market Cap to Future Revenue Ratio